Human	B-OG
breast	B-DS
cancer	I-DS
cells	O
educate	O
macrophages	O
toward	O
the	O
M2	O
activation	O
status	O

Introduction	O

The	O
immune	O
system	O
plays	O
a	O
major	O
role	O
in	O
cancer	B-DS
progression	O
.	O

In	O
solid	B-DS
tumors	I-DS
,	O
5	O
-	O
40	O
%	O
of	O
the	O
tumor	B-DS
mass	O
consists	O
of	O
tumor	B-DS
-	O
associated	O
macrophages	O
(	O
TAMs	O
)	O
and	O
there	O
is	O
usually	O
a	O
correlation	O
between	O
the	O
number	O
of	O
TAMs	O
and	O
poor	O
prognosis	O
,	O
depending	O
on	O
the	O
tumor	B-DS
type	O
.	O

TAMs	O
usually	O
resemble	O
M2	O
macrophages	O
.	O

Unlike	O
M1	O
-	O
macrophages	O
which	O
have	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
cancer	B-DS
functions	O
,	O
M2	O
-	O
macrophages	O
are	O
immunosuppressive	O
,	O
contribute	O
to	O
the	O
matrix	O
-	O
remodeling	O
,	O
and	O
hence	O
favor	O
tumor	B-DS
growth	O
.	O

The	O
role	O
of	O
TAMs	O
is	O
not	O
fully	O
understood	O
in	O
breast	B-DS
cancer	I-DS
progression	O
.	O

Methods	O

Macrophage	O
infiltration	O
(	O
CD68	B-GP
)	O
and	O
activation	O
status	O
(	O
HLA	B-GP
-	I-GP
DRIIα	I-GP
,	O
CD163	B-GP
)	O
were	O
evaluated	O
in	O
a	O
large	O
cohort	O
of	O
human	B-OG
primary	O
breast	B-DS
tumors	I-DS
(	O
562	O
tissue	O
microarray	O
samples	O
),	O
by	O
immunohistochemistry	O
and	O
scored	O
by	O
automated	O
image	O
analysis	O
algorithms	O
.	O

Survival	O
between	O
groups	O
was	O
compared	O
using	O
the	O
Kaplan	O
-	O
Meier	O
life	O
-	O
table	O
method	O
and	O
a	O
Cox	O
multivariate	O
proportional	O
hazards	O
model	O
.	O

Macrophage	O
education	O
by	O
breast	B-DS
cancer	I-DS
cells	O
was	O
assessed	O
by	O
ex	O
vivo	O
differentiation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
breast	B-DS
cancer	I-DS
cell	O
conditioned	O
media	O
(	O
MDA	O
-	O
MB231	O
,	O
MCF	O
-	O
7	O
or	O
T47D	O
cell	O
lines	O
)	O
and	O
M1	O
or	O
M2	O
inducing	O
cytokines	B-GP
(	O
respectively	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
).	O

Obtained	O
macrophages	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
CD14	B-GP
,	O
CD16	B-GP
,	O
CD64	B-GP
,	O
CD86	B-GP
,	O
CD200R	B-GP
and	O
CD163	B-GP
),	O
ELISA	O
(	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
monocyte	B-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
M	B-GP
-	I-GP
CSF	I-GP
)	O
and	O
zymography	O
(	O
matrix	B-GP
metalloproteinase	I-GP
9	I-GP
,	O
MMP	B-GP
-	I-GP
9	I-GP
).	O

Results	O

Clinically	O
,	O
we	O
found	O
that	O
high	O
numbers	O
of	O
CD163	B-GP
+	O
M2	O
-	O
macrophages	O
were	O
strongly	O
associated	O
with	O
fast	O
proliferation	O
,	O
poor	O
differentiation	O
,	O
estrogen	B-GP
receptor	I-GP
negativity	O
and	O
histological	O
ductal	O
type	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
studied	O
cohort	O
of	O
human	B-OG
primary	O
breast	B-DS
tumors	I-DS
.	O

We	O
demonstrated	O
ex	O
vivo	O
that	O
breast	B-DS
cancer	I-DS
cell	O
-	O
secreted	O
factors	O
modulate	O
macrophage	O
differentiation	O
toward	O
the	O
M2	O
phenotype	O
.	O

Furthermore	O
,	O
the	O
more	O
aggressive	O
mesenchymal	O
-	O
like	O
cell	O
line	O
MDA	O
-	O
MB231	O
,	O
which	O
secretes	O
high	O
levels	O
of	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
skews	O
macrophages	O
toward	O
the	O
more	O
immunosuppressive	O
M2c	O
subtype	O
.	O

Conclusions	O

This	O
study	O
demonstrates	O
that	O
human	B-OG
breast	B-DS
cancer	I-DS
cells	O
influence	O
macrophage	O
differentiation	O
and	O
that	O
TAM	O
differentiation	O
status	O
correlates	O
with	O
recurrence	O
free	O
survival	O
,	O
thus	O
further	O
emphasizing	O
that	O
TAMs	O
can	O
similarly	O
affect	O
therapy	O
efficacy	O
and	O
patient	O
outcome	O
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s13058	O
-	O
015	O
-	O
0621	O
-	O
0	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Introduction	O

Metastasis	O
is	O
often	O
explained	O
with	O
the	O
‘	O
seed	O
and	O
soil	O
’	O
theory	O
.	O

Conceptually	O
,	O
it	O
implies	O
that	O
the	O
cancer	B-DS
cell	O
(	O
seed	O
)	O
undergoes	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
),	O
invades	O
vessels	O
,	O
becomes	O
a	O
circulating	O
tumor	B-DS
cell	O
(	O
CTC	O
),	O
migrates	O
,	O
extravasates	O
,	O
undergoes	O
mesenchymal	O
to	O
epithelial	O
transition	O
,	O
and	O
eventually	O
colonizes	O
distant	O
sites	O
as	O
a	O
disseminating	O
tumor	B-DS
cell	O
(	O
DTC	O
).	O
‘	O
Soil	O
’	O
relates	O
to	O
tumor	B-DS
microenvironment	O
elements	O
which	O
contribute	O
to	O
these	O
processes	O
,	O
making	O
the	O
distant	O
sites	O
permissive	O
to	O
colonization	O
by	O
CTCs	O
or	O
DTCs	O
[	O
1	O
].	O

The	O
immune	O
system	O
is	O
a	O
major	O
player	O
in	O
the	O
cancer	B-DS
cell	O
/	O
tumor	B-DS
microenvironment	O
crosstalk	O
.	O

In	O
solid	B-DS
tumors	I-DS
,	O
5	O
−	O
40	O
%	O
of	O
the	O
tumor	B-DS
mass	O
consists	O
of	O
tumor	B-DS
-	O
associated	O
macrophages	O
(	O
TAMs	O
).	O

Approximately	O
80	O
%	O
of	O
the	O
publications	O
in	O
this	O
field	O
report	O
an	O
association	O
between	O
TAMs	O
and	O
poor	O
prognosis	O
[	O
2	O
,	O
3	O
].	O

In	O
humans	B-OG
macrophage	O
polarization	O
is	O
a	O
continuum	O
that	O
spans	O
two	O
extremes	O
from	O
the	O
classically	O
activated	O
M1	O
macrophages	O
to	O
the	O
alternatively	O
activated	O
M2	O
macrophages	O
.	O

M1	O
macrophages	O
derive	O
from	O
interferon	B-GP
γ	I-GP
(	O
IFN	B-GP
-	I-GP
γ	I-GP
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimuli	O
and	O
secrete	O
inflammatory	B-GP
cytokines	I-GP
(	O
e	O
.	O
g	O
.,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
),	O
reactive	O
nitrogen	O
species	O
(	O
RN	O
)	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
).	O

The	O
validated	O
surface	O
-	O
markers	O
of	O
human	B-OG
M1	O
macrophages	O
include	O
high	O
levels	O
of	O
CD14	B-GP
and	O
CD16	B-GP
,	O
CD64	B-GP
,	O
CD86	B-GP
and	O
HLA	B-GP
-	I-GP
DRα	I-GP
[	O
4	O
,	O
5	O
].	O

M2	O
macrophages	O
,	O
can	O
be	O
further	O
divided	O
into	O
M2a	O
,	O
M2b	O
and	O
M2c	O
macrophages	O
.	O

M2a	O
macrophages	O
arise	O
from	O
IL	B-GP
-	I-GP
4	I-GP
or	O
IL	B-GP
-	I-GP
13	I-GP
stimuli	O
and	O
release	O
matrix	O
-	O
remodeling	O
cytokines	B-GP
.	O

Elevated	O
expression	O
of	O
CD200R	B-GP
and	O
CD86	B-GP
is	O
a	O
validated	O
phenotypic	O
marker	O
of	O
M2a	O
macrophages	O
[	O
4	O
,	O
5	O
].	O

M2b	O
macrophages	O
result	O
from	O
the	O
recognition	O
of	O
immune	O
complexes	O
in	O
combination	O
with	O
IL	B-GP
-	I-GP
1β	I-GP
or	O
LPS	O
stimuli	O
and	O
like	O
M2a	O
macrophages	O
,	O
they	O
are	O
involved	O
in	O
wound	O
healing	O
.	O

The	O
immunosuppressive	O
M2c	O
-	O
macrophages	O
are	O
the	O
outcome	O
of	O
IL	B-GP
-	I-GP
10	I-GP
,	O
TGF	B-GP
-	I-GP
β	I-GP
(	O
transforming	B-GP
growth	I-GP
factor	I-GP
β	I-GP
),	O
glucocorticoids	O
or	O
immune	O
complex	O
rich	O
environments	O
.	O

M2c	O
macrophages	O
generate	O
further	O
IL	B-GP
-	I-GP
10	I-GP
and	O
matrix	O
-	O
remodeling	O
factors	O
such	O
as	O
matrix	B-GP
metalloproteinases	I-GP
(	O
MMPs	B-GP
)	O
[	O
4	O
,	O
5	O
].	O

Elevated	O
CD163	B-GP
expression	O
is	O
a	O
validated	O
marker	O
of	O
M2c	O
polarization	O
[	O
5	O
].	O

TAMs	O
,	O
a	O
macrophage	O
population	O
recruited	O
and	O
educated	O
by	O
tumor	B-DS
cells	O
,	O
which	O
are	O
therefore	O
exposed	O
to	O
IL	B-GP
-	I-GP
10	I-GP
,	O
TGF	B-GP
-	I-GP
β	I-GP
,	O
M	B-GP
-	I-GP
CSF	I-GP
(	O
monocyte	B-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
)	O
[	O
6	O
]	O
and	O
other	O
immunosuppressive	O
stimuli	O
[	O
7	O
],	O
are	O
more	O
closely	O
related	O
to	O
the	O
M2	O
type	O
[	O
8	O
].	O

In	O
the	O
tumor	B-DS
microenvironment	O
,	O
TAMs	O
will	O
preferentially	O
perform	O
trophic	O
and	O
immunosuppressive	O
rather	O
than	O
immune	O
effector	O
tasks	O
[	O
3	O
,	O
9	O
,	O
10	O
].	O

Hence	O
,	O
TAMs	O
promote	O
epithelial	O
outgrowth	O
and	O
invasion	O
,	O
which	O
are	O
common	O
features	O
of	O
development	O
and	O
cancer	B-DS
[	O
3	O
,	O
9	O
].	O

Wickoff	O
et	O
al	O
.	O
have	O
shown	O
that	O
mammary	B-DS
tumors	I-DS
exhibit	O
a	O
paracrine	O
loop	O
between	O
TAMs	O
and	O
cancer	B-DS
cells	O
.	O

TAMs	O
express	O
monocyte	B-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
receptor	I-GP
(	O
M	B-GP
-	I-GP
CSFR	I-GP
,	O
also	O
known	O
as	O
CSF	B-GP
-	I-GP
1R	I-GP
or	O
cFMS	B-GP
),	O
which	O
binds	O
monocyte	B-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
(	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
also	O
known	O
as	O
CSF	B-GP
-	I-GP
1	I-GP
)	O
secreted	O
by	O
cancer	B-DS
cells	O
.	O

Conversely	O
,	O
TAMs	O
secrete	O
epidermal	B-GP
growth	I-GP
factor	I-GP
(	O
EGF	B-GP
)	O
and	O
activate	O
the	O
EGF	B-GP
receptor	I-GP
(	O
EGFR	B-GP
)	O
on	O
the	O
cancer	B-DS
cells	O
.	O

This	O
allows	O
co	O
-	O
migration	O
of	O
the	O
two	O
cell	O
types	O
,	O
thus	O
,	O
enhancing	O
motility	O
and	O
subsequent	O
invasion	O
of	O
healthy	O
surrounding	O
tissue	O
and	O
intravasation	O
[	O
11	O
,	O
12	O
].	O

Also	O
,	O
breast	B-DS
cancer	I-DS
cell	O
leucocyte	B-GP
receptor	I-GP
,	O
vascular	B-GP
cell	I-GP
adhesion	I-GP
molecule	I-GP
1	I-GP
(	O
VCAM1	B-GP
)	O
binding	O
to	O
TAM	O
α4	B-GP
-	I-GP
integrin	I-GP
explains	O
the	O
increased	O
survival	O
of	O
VCAM1	B-GP
+	O
tumor	B-DS
cells	O
in	O
leucocyte	O
-	O
rich	O
environments	O
[	O
13	O
].	O

Like	O
their	O
phenotype	O
and	O
interactions	O
with	O
tumor	B-DS
cells	O
,	O
the	O
location	O
of	O
TAMs	O
in	O
relation	O
to	O
hypoxic	O
areas	O
is	O
a	O
key	O
parameter	O
controlling	O
tumor	B-DS
growth	O
.	O

In	O
addition	O
to	O
the	O
perivascular	O
TAMs	O
,	O
which	O
take	O
part	O
in	O
cancer	B-DS
cell	O
invasion	O
[	O
11	O
,	O
12	O
],	O
TAMs	O
are	O
also	O
recruited	O
into	O
hypoxic	O
areas	O
[	O
14	O
].	O

Within	O
these	O
avascular	O
areas	O
TAMs	O
alter	O
their	O
gene	O
expression	O
profile	O
,	O
favoring	O
a	O
pro	O
-	O
tumor	B-DS
M2	O
phenotype	O
[	O
15	O
].	O

This	O
may	O
explain	O
why	O
in	O
the	O
early	O
stages	O
[	O
16	O
]	O
of	O
cancers	B-DS
of	O
the	O
lung	O
[	O
17	O
],	O
colon	O
[	O
18	O
]	O
and	O
stomach	O
[	O
19	O
],	O
the	O
macrophages	O
in	O
the	O
normoxic	O
milieu	O
display	O
an	O
M1	O
phenotype	O
and	O
are	O
associated	O
with	O
good	O
prognosis	O
.	O

Immunohistopathological	O
breast	B-DS
carcinoma	I-DS
studies	O
with	O
restricted	O
numbers	O
of	O
samples	O
(	O
n	O
=	O
53	O
and	O
120	O
,	O
respectively	O
)	O
reveal	O
a	O
gradual	O
increase	O
in	O
the	O
amount	O
of	O
infiltrating	O
macrophages	O
(	O
CD68	B-GP
+)	O
from	O
normal	O
breast	O
tissue	O
to	O
benign	B-DS
proliferative	I-DS
breast	I-DS
disease	I-DS
,	O
ductal	B-DS
carcinoma	I-DS
in	I-DS
situ	I-DS
(	O
DCIS	B-DS
)	O
and	O
infiltrating	B-DS
ductal	I-DS
carcinoma	I-DS
[	O
20	O
,	O
21	O
].	O

Two	O
larger	O
studies	O
(	O
n	O
=	O
1	O
,	O
322	O
and	O
168	O
,	O
respectively	O
)	O
confirmed	O
that	O
CD68	B-GP
+	O
macrophages	O
were	O
associated	O
with	O
higher	O
tumor	B-DS
grade	O
,	O
estrogen	B-GP
receptor	I-GP
(	O
ER	B-GP
)	O
and	O
progesterone	B-GP
receptor	I-GP
(	O
PR	B-GP
)	O
negativity	O
,	O
human	B-GP
epithelial	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
2	I-GP
(	O
HER	B-GP
-	I-GP
2	I-GP
)	O
positivity	O
and	O
a	O
basal	O
phenotype	O
,	O
but	O
led	O
to	O
the	O
conclusion	O
that	O
CD68	B-GP
expression	O
was	O
not	O
an	O
independent	O
prognostic	O
factor	O
[	O
22	O
,	O
23	O
].	O

Another	O
breast	B-DS
cancer	I-DS
cohort	O
study	O
(	O
n	O
=	O
144	O
),	O
looking	O
at	O
total	O
macrophage	O
number	O
(	O
CD68	B-GP
+)	O
and	O
M2	O
macrophages	O
(	O
CD163	B-GP
+)	O
found	O
that	O
CD163	B-GP
was	O
also	O
associated	O
with	O
other	O
prognostic	O
markers	O
[	O
24	O
].	O

It	O
showed	O
that	O
CD68	B-GP
+	O
cells	O
in	O
the	O
tumor	B-DS
stroma	O
but	O
not	O
in	O
the	O
tumor	B-DS
nest	O
were	O
an	O
independent	O
prognostic	O
factor	O
for	O
decreased	O
cancer	B-DS
-	O
specific	O
survival	O
,	O
accounting	O
for	O
the	O
localization	O
of	O
TAMs	O
in	O
the	O
tumors	B-DS
more	O
than	O
their	O
mere	O
presence	O
.	O

Triple	O
-	O
negative	O
/	O
basal	O
-	O
like	O
breast	B-DS
tumor	I-DS
stroma	O
had	O
more	O
CD163	B-GP
+	O
and	O
CD68	B-GP
+	O
cells	O
and	O
a	O
higher	O
proportion	O
of	O
CD163	B-GP
relative	O
to	O
CD68	B-GP
when	O
compared	O
to	O
the	O
stroma	O
of	O
luminal	O
A	O
tumors	B-DS
.	O

This	O
indicates	O
a	O
predominance	O
of	O
mature	O
M2	O
macrophages	O
and	O
possibly	O
immature	O
myeloid	O
-	O
derived	O
cells	O
(	O
MDCs	O
,	O
also	O
CD163	B-GP
+)	O
in	O
triple	O
-	O
negative	O
disease	O
[	O
24	O
].	O

Several	O
clinical	O
studies	O
have	O
found	O
an	O
association	O
between	O
macrophage	O
infiltration	O
and	O
angiogenesis	O
in	O
breast	B-DS
cancer	I-DS
[	O
22	O
,	O
25	O
–	O
28	O
].	O

However	O
,	O
in	O
relation	O
to	O
prognosis	O
it	O
is	O
unanimous	O
that	O
larger	O
studies	O
of	O
macrophage	O
subpopulations	O
are	O
needed	O
.	O

This	O
study	O
intends	O
to	O
fill	O
that	O
gap	O
.	O

Focusing	O
on	O
the	O
expression	O
of	O
M1	O
and	O
M2	O
markers	O
in	O
samples	O
from	O
a	O
large	O
cohort	O
of	O
patients	O
with	O
breast	B-DS
cancer	I-DS
(	O
n	O
=	O
562	O
),	O
we	O
looked	O
for	O
possible	O
associations	O
with	O
tumor	B-DS
progression	O
.	O

Additionally	O
,	O
by	O
studying	O
the	O
ex	O
vivo	O
differentiation	O
of	O
human	B-OG
macrophages	O
in	O
the	O
presence	O
of	O
breast	B-DS
cancer	I-DS
conditioned	O
media	O
(	O
CM	O
),	O
we	O
aimed	O
to	O
find	O
possible	O
mechanisms	O
of	O
TAM	O
education	O
.	O

To	O
achieve	O
these	O
aims	O
,	O
we	O
revisited	O
tissue	O
microarrays	O
from	O
a	O
large	O
cohort	O
[	O
29	O
]	O
of	O
early	O
human	B-OG
breast	B-DS
tumors	I-DS
of	O
different	O
subtypes	O
,	O
grades	O
and	O
aggressiveness	O
and	O
used	O
different	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
.	O

Methods	O

Human	B-OG
samples	O

TMA	O
samples	O
(	O
n	O
=	O
562	O
out	O
of	O
1	O
,	O
199	O
patients	O
from	O
the	O
FinXX	O
study	O
,	O
NCT00114816	O
[	O
29	O
])	O
were	O
studied	O
retrospectively	O
.	O

Clinicopathological	O
characteristics	O
of	O
the	O
sub	O
-	O
cohort	O
are	O
described	O
in	O
Table	O
1	O
.	O

Formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tumor	B-DS
samples	O
were	O
used	O
for	O
TMA	O
.	O

Blocks	O
were	O
made	O
using	O
a	O
1	O
.	O
0	O
-	O
mm	O
tissue	O
cylinder	O
through	O
a	O
histologically	O
representative	O
area	O
of	O
each	O
donor	O
tumor	B-DS
block	O
.	O

From	O
each	O
donor	O
block	O
,	O
2	O
–	O
4	O
cores	O
were	O
cut	O
and	O
15	O
TMA	O
blocks	O
were	O
prepared	O
,	O
each	O
containing	O
61	O
–	O
84	O
tumor	B-DS
samples	O
plus	O
2	O
–	O
3	O
liver	O
samples	O
as	O
positive	O
controls	O
.	O
Table	O
1Patient	O
demographics	O
and	O
relevant	O
clinical	O
characteristicsFactorEntire	O
seriesCD68a	O
P	O
b	O
CD163a	O
P	O
b	O
HLA	O
-	O
Drαa	O
P	O
b	O
≤	O
369	O
>	O
369	O
≤	O
167	O
.	O
5	O
>	O
167	O
.	O
5	O
≤	O
107	O
>	O
107n	O
=	O
562n	O
=	O
277n	O
=	O
274n	O
=	O
270n	O
=	O
267n	O
=	O
280n	O
=	O
275Age	O
,	O
years	O
≤	O
502139511310598112100	O
>	O
503491821610	O
.	O
0931651690	O
.	O
6021681750	O
.	O
378Tumor	B-DS
size	O
median	O
≤	O
22	O
mm283144132137129140138	O
>	O
22	O
mm2781321420	O
.	O
3481321380	O
.	O
5451391371	O
.	O
000N	O
.	O
A	O
.	O
1Nodal	O
statuspN065273728333728pN	O
+	O
4972502370	O
.	O
1692422340	O
.	O
4682432470	O
.	O
267Histological	O
typeDuctal399181211171213204192Lobular110664369334760Other5330200	O
.	O
0103021	O
<	O
0	O
.	O
00129230	O
.	O
274Histological	O
gradeGrade	O
146331326162025Grade	O
226413811915397127132Grade	O
32501061400	O
.	O
00191152	O
<	O
0	O
.	O
0011311180	O
.	O
518N	O
.	O
A	O
.	O
2ER	O
statusPositive405215181214171191207Negative15762930	O
.	O
0035696	O
<	O
0	O
.	O
00189680	O
.	O
065HER	O
-	O
2	O
statusPositive170858372939377Negative3921921910	O
.	O
9201981740	O
.	O
0401871980	O
.	O
183Biological	O
groupER	O
+,	O
HER	B-GP
-	I-GP
2	I-GP
−	O
314165142173123139168ER	O
+,	O
HER2	B-GP
+	O
91503941485239ER	O
-,	O
HER2	B-GP
+	O
79354431454138ER	O
-,	O
HER2	B-GP
−	O
7827490	O
.	O
0152551	O
<	O
0	O
.	O
00148300	O
.	O
032Ki67	O
≤	O
20	O
%	O
27114911615896124140	O
>	O
20	O
%	O
2421041340	O
.	O
00592144	O
<	O
0	O
.	O
0011261160	O
.	O
252N	O
.	O
A	O
.	O
49Results	O
are	O
presented	O
as	O
number	O
of	O
patients	O
.	O
aThe	O
cutoff	O
values	O
used	O
correspond	O
to	O
the	O
median	O
values	O
of	O
number	O
of	O
positive	O
cells	O
in	O
the	O
entire	O
series	O
.	O
bChi	O
-	O
square	O
test	O
.	O
ER	B-GP
estrogen	B-GP
receptor	I-GP
,	O
HER	B-GP
-	I-GP
2	I-GP
human	B-GP
epidermal	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
2	I-GP
,	O
N	O
.	O
A	O
.	O
not	O
available	O

Immunohistochemical	O
analysis	O

Sections	O
(	O
4	O
-	O
μm	O
)	O
of	O
the	O
TMA	O
blocks	O
were	O
stained	O
using	O
standard	O
immunohistochemical	O
techniques	O
for	O
the	O
expression	O
of	O
CD68	B-GP
(	O
anti	O
-	O
SA2	B-GP
antibody	O
clone	O
3C6	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
),	O
CD163	B-GP
(	O
clone	O
10D6	O
,	O
Novocastra	O
,	O
Newcastle	O
,	O
UK	O
)	O
and	O
HLA	B-GP
-	I-GP
DRα	I-GP
(	O
Dako	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
[	O
30	O
,	O
31	O
]	O
(	O
detailed	O
information	O
provided	O
in	O
Additional	O
file	O
1	O
).	O

All	O
the	O
stained	O
TMA	O
slides	O
were	O
scanned	O
using	O
an	O
Olympus	O
virtual	O
microscope	O
equipped	O
with	O
Dotslide	O
using	O
the	O
10	O
×	O
objective	O
(	O
Olympus	O
BX51	O
,	O
Olympus	O
,	O
Munich	O
,	O
Germany	O
),	O
and	O
AxioCam	O
camera	O
(	O
Zeiss	O
,	O
Jena	O
,	O
Germany	O
).	O

Positively	O
stained	O
cells	O
were	O
counted	O
using	O
Fiji	O
equipment	O
version	O
1	O
.	O
48s	O
(	O
Wayne	O
Rasband	O
,	O
NIH	O
).	O

After	O
color	O
deconvolution	O
for	O
hematoxylin	O
and	O
3	O
,	O
3	O
’-	O
Diaminobenzidine	O
(	O
DAB	O
),	O
the	O
threshold	O
was	O
set	O
for	O
macrophage	O
visualization	O
.	O

The	O
size	O
limit	O
for	O
particle	O
analysis	O
was	O
carefully	O
chosen	O
to	O
include	O
only	O
macrophages	O
.	O

Damaged	O
samples	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

The	O
data	O
were	O
analyzed	O
in	O
a	O
double	O
-	O
blinded	O
fashion	O
.	O

The	O
investigators	O
were	O
blinded	O
to	O
the	O
identity	O
and	O
clinical	O
pathological	O
characteristics	O
of	O
each	O
sample	O
while	O
analyzing	O
/	O
scoring	O
the	O
macrophage	O
content	O
and	O
differentiation	O
status	O
.	O

The	O
final	O
numbers	O
of	O
positive	O
cells	O
per	O
marker	O
,	O
per	O
sample	O
were	O
passed	O
on	O
to	O
hypothesis	O
-	O
naïve	O
investigators	O
who	O
performed	O
the	O
statistical	O
analysis	O
of	O
the	O
cohort	O
.	O

Cell	O
culture	O

Human	B-OG
breast	B-DS
cancer	I-DS
cell	O
lines	O
MCF	O
-	O
7	O
,	O
MDA	O
-	O
MB231	O
and	O
T47D	O
,	O
obtained	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
),	O
were	O
grown	O
in	O
Roswell	O
Park	O
Memorial	O
Institure	O
(	O
RPMI	O
)-	O
1640	O
medium	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
(	O
Gibco	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
and	O
100	O
IU	O
/	O
ml	O
penicillin	O
and	O
streptomycin	O
(	O
Gibco	O
,	O
Bleiswijk	O
,	O
Netherlands	O
)	O
at	O
37	O
°	O
C	O
in	O
a	O
5	O
%	O
CO2	O
atmosphere	O
.	O

After	O
reaching	O
confluence	O
,	O
cell	O
culture	O
medium	O
was	O
changed	O
to	O
medium	O
containing	O
only	O
1	O
%	O
FBS	O
and	O
kept	O
in	O
culture	O
for	O
72	O
h	O
.	O

At	O
the	O
end	O
of	O
the	O
culture	O
period	O
,	O
the	O
CM	O
were	O
collected	O
from	O
at	O
least	O
three	O
independent	O
cell	O
line	O
batches	O
from	O
each	O
cell	O
type	O
.	O

The	O
CM	O
were	O
centrifuged	O
for	O
5	O
minutes	O
at	O
2	O
,	O
800	O
g	O
,	O
aliquoted	O
and	O
frozen	O
at	O
−	O
20	O
°	O
C	O
.	O

CM	O
were	O
used	O
as	O
50	O
%	O
supplement	O
of	O
the	O
macrophage	O
differentiation	O
culture	O
medium	O
together	O
with	O
10	O
%	O
FBS	O
.	O

The	O
cell	O
lines	O
were	O
recently	O
authenticated	O
by	O
STR	O
(	O
Short	O
tandem	O
repeat	O
)	O
profiling	O
by	O
a	O
certified	O
cell	O
line	O
authentication	O
service	O
(	O
DDC	O
Medical	O
,	O
Fisher	O
Scientific	O
,	O
London	O
,	O
UK	O
).	O

Mycoplasma	B-OG
detection	O
was	O
performed	O
on	O
a	O
routine	O
basis	O
by	O
4	O
’,	O
6	O
-	O
Diamidino	O
-	O
2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
staining	O
of	O
cultured	O
cells	O
.	O

Peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
isolation	O

PBMCs	O
from	O
five	O
different	O
donors	O
were	O
isolated	O
by	O
centrifugation	O
over	O
Ficoll	O
gradient	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

CD14	B-GP
+	O
cells	O
were	O
magnetically	O
labeled	O
with	O
α	B-GP
-	I-GP
CD14	I-GP
microbeads	O
and	O
positively	O
selected	O
by	O
MACS	O
technology	O
(	O
Miltenyi	O
Biotec	O
,	O
Cologne	O
,	O
Germany	O
).	O

Macrophage	O
differentiation	O

To	O
obtain	O
M1	O
,	O
M2a	O
and	O
M2c	O
macrophages	O
,	O
CD14	B-GP
+	O
monocytes	O
were	O
cultured	O
in	O
MEM	O
(	O
Lonza	O
,	O
Basel	O
,	O
Switzerland	O
)	O
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
Gibco	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
(	O
control	O
,	O
CTR	O
),	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
50	O
ng	O
/	O
ml	O
;	O
M1	O
),	O
or	O
IL	B-GP
-	I-GP
4	I-GP
(	O
50	O
ng	O
/	O
ml	O
;	O
M2a	O
),	O
or	O
IL	B-GP
-	I-GP
10	I-GP
(	O
50	O
ng	O
/	O
ml	O
;	O
M2c	O
)	O
for	O
5	O
days	O
with	O
replacement	O
of	O
half	O
of	O
the	O
culture	O
media	O
at	O
day	O
3	O
[	O
32	O
].	O

To	O
assess	O
the	O
effect	O
of	O
breast	B-DS
cancer	I-DS
cell	O
-	O
line	O
-	O
secreted	O
factors	O
,	O
the	O
same	O
differentiation	O
protocol	O
was	O
carried	O
out	O
in	O
the	O
presence	O
or	O
absence	O
of	O
50	O
%	O
CM	O
from	O
MDA	O
-	O
MB231	O
,	O
MCF	O
-	O
7	O
or	O
T47D	O
cells	O
.	O

For	O
activation	O
status	O
experiments	O
(	O
ELISA	O
),	O
cells	O
were	O
treated	O
with	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
for	O
one	O
additional	O
day	O
.	O

Unless	O
otherwise	O
stated	O
,	O
all	O
the	O
used	O
cytokines	B-GP
were	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
).	O

Supernatants	O
were	O
collected	O
,	O
centrifuged	O
for	O
5	O
minutes	O
at	O
2	O
,	O
800	O
g	O
,	O
aliquoted	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
until	O
further	O
analysis	O
.	O

Cells	O
were	O
harvested	O
with	O
Accutase	O
(	O
Invitrogen	O
,	O
Paisley	O
,	O
UK	O
),	O
debris	O
were	O
removed	O
by	O
centrifugation	O
(	O
5	O
minutes	O
at	O
400	O
g	O
),	O
and	O
cells	O
were	O
used	O
for	O
flow	O
cytometry	O
analysis	O
.	O

Supernatants	O
were	O
used	O
for	O
ELISA	O
and	O
zymography	O
.	O

Flow	O
cytometry	O

Ex	O
vivo	O
polarized	O
macrophages	O
were	O
analyzed	O
by	O
validated	O
flow	O
cytometry	O
methods	O
[	O
5	O
],	O
with	O
the	O
BD	O
LSR	O
II	O
flow	O
cytometer	O
(	O
BD	O
Biosciences	O
,	O
Erembodegem	O
-	O
Dorp	O
,	O
Belgium	O
).	O

In	O
brief	O
,	O
cells	O
were	O
washed	O
with	O
PBS	O
0	O
.	O
1	O
%	O
BSA	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
and	O
before	O
staining	O
,	O
Fc	B-GP
receptors	I-GP
were	O
blocked	O
with	O
FcR	B-GP
blocking	O
reagent	O
(	O
BD	O
Biosciences	O
,	O
Erembodegem	O
-	O
Dorp	O
,	O
Belgium	O
):	O
0	O
.	O
2	O
×	O
106	O
cells	O
were	O
incubated	O
with	O
adequate	O
antibody	O
mixes	O
and	O
washed	O
prior	O
to	O
analysis	O
.	O

Surface	O
-	O
marker	O
expression	O
was	O
analyzed	O
with	O
flow	O
cytometry	O
using	O
the	O
following	O
fluorochrome	O
-	O
labeled	O
monoclonal	O
antibodies	B-GP
:	O
CD14	B-GP
-	O
APC	B-GP
-	O
Cy7	O
(	O
clone61D3	O
;	O
eBioscience	O
,	O
Paris	O
,	O
France	O
),	O
CD16	B-GP
-	O
PE	O
-	O
Cy7	O
(	O
clone	O
DJ130c	O
;	O
AbD	O
Serotec	O
,	O
Kidlington	O
,	O
UK	O
),	O
CD64	B-GP
-	O
AF488	O
(	O
clone	O
10	O
.	O
1	O
;	O
BioLegend	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
),	O
CD200R	B-GP
-	O
PE	O
(	O
clone	O
OX108	O
;	O
AbD	O
Serotec	O
,	O
Kidlington	O
,	O
UK	O
),	O
CD163	B-GP
-	O
AF647	O
(	O
clone	O
GHI	O
/	O
61	O
;	O
BD	O
Pharmingen	O
,	O
Erembodegem	O
-	O
Dorp	O
,	O
Belgium	O
),	O
and	O
CD86	B-GP
-	O
AF488	O
(	O
clone	O
IT2	O
.	O
2	O
,	O
BD	O
Pharmingen	O
,	O
Erembodegem	O
-	O
Dorp	O
,	O
Belgium	O
).	O

Equivalent	O
amounts	O
of	O
isotype	O
-	O
matched	O
control	O
antibodies	B-GP
and	O
unstained	O
cells	O
were	O
included	O
in	O
all	O
experiments	O
as	O
negative	O
and	O
autofluorescence	O
controls	O
.	O

Data	O
were	O
analyzed	O
with	O
BD	O
FACSDiva	O
software	O
,	O
after	O
gating	O
on	O
the	O
myeloid	O
population	O
in	O
the	O
FSC	O
/	O
SSC	O
plot	O
.	O

Values	O
were	O
expressed	O
as	O
the	O
percent	O
ratio	O
of	O
the	O
median	O
fluorescence	O
intensity	O
(	O
MedFI	O
)	O
of	O
the	O
marker	O
of	O
interest	O
over	O
the	O
MedFI	O
of	O
the	O
unstained	O
cells	O
.	O

ELISA	O

LPS	O
-	O
activated	O
macrophage	O
culture	O
supernatants	O
were	O
used	O
in	O
ELISA	O
for	O
quantification	O
of	O
h	O
-	O
IL	B-GP
-	I-GP
10	I-GP
,	O
h	O
-	O
IL	B-GP
-	I-GP
8	I-GP
,	O
and	O
h	O
-	O
IL	B-GP
-	I-GP
6	I-GP
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
(	O
R	O
&	O
D	O
systems	O
).	O

h	O
-	O
M	B-GP
-	I-GP
CSF	I-GP
was	O
quantified	O
in	O
breast	B-DS
cancer	I-DS
cell	O
line	O
CM	O
(	O
Duo	O
set	O
,	O
R	O
&	O
D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
).	O

Zymography	O

The	O
potential	O
proteolytic	O
activity	O
of	O
MMPs	B-GP
in	O
the	O
supernatants	O
of	O
the	O
obtained	O
macrophages	O
was	O
determined	O
by	O
zymography	O
as	O
previously	O
described	O
[	O
33	O
].	O

The	O
stained	O
polyacrylamide	O
-	O
gelatin	O
gels	O
were	O
observed	O
with	O
the	O
Image	O
Quant	O
RT	O
ECL	O
imager	O
.	O

Densitometry	O
of	O
the	O
bands	O
corresponding	O
to	O
pro	O
-	O
MMP	B-GP
-	I-GP
9	I-GP
activity	O
(	O
92	O
kDa	O
)	O
was	O
performed	O
using	O
Fiji	O
equipment	O
version	O
1	O
.	O
48s	O
(	O
Wayne	O
Rasband	O
,	O
NIH	O
).	O

Presented	O
values	O
are	O
the	O
optical	O
densities	O
of	O
pro	O
-	O
MMP	B-GP
-	I-GP
9	I-GP
-	O
digested	O
bands	O
normalized	O
to	O
the	O
total	O
protein	O
content	O
of	O
the	O
corresponding	O
total	O
cell	O
lysate	O
compared	O
with	O
the	O
density	O
of	O
the	O
equivalent	O
background	O
area	O
.	O

Statistics	O

TMA	O
results	O
were	O
analyzed	O
with	O
SAS	O
version	O
8	O
.	O
2	O
for	O
Windows	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
using	O
the	O
median	O
values	O
of	O
the	O
numbers	O
of	O
positive	O
cells	O
in	O
the	O
entire	O
series	O
as	O
the	O
cutoff	O
value	O
.	O

Frequency	O
tables	O
were	O
analyzed	O
using	O
the	O
chi	O
-	O
square	O
(	O
χ2	O
)	O
test	O
.	O

Survival	O
between	O
groups	O
was	O
compared	O
using	O
the	O
Kaplan	O
-	O
Meier	O
life	O
-	O
table	O
method	O
and	O
a	O
Cox	O
multivariate	O
proportional	O
hazards	O
model	O
.	O

The	O
log	O
-	O
rank	O
test	O
was	O
used	O
to	O
confirm	O
the	O
robustness	O
of	O
the	O
analysis	O
.	O

The	O
subgroup	O
analyses	O
were	O
performed	O
including	O
the	O
macrophage	O
markers	O
,	O
the	O
subgroup	O
variable	O
,	O
and	O
their	O
interaction	O
in	O
the	O
Cox	O
model	O
.	O

The	O
Mann	O
-	O
Whitney	O
or	O
Kruskal	O
-	O
Wallis	O
tests	O
were	O
applied	O
when	O
suitable	O
.	O

All	O
P	O
values	O
are	O
two	O
-	O
sided	O
and	O
are	O
not	O
adjusted	O
for	O
multiple	O
testing	O
.	O

Experimental	O
data	O
were	O
expressed	O
as	O
median	O
±	O
SD	O
,	O
unless	O
otherwise	O
indicated	O
.	O

The	O
Kruskal	O
-	O
Wallis	O
test	O
followed	O
by	O
Dunn	O
’	O
s	O
post	O
hoc	O
test	O
was	O
employed	O
to	O
calculate	O
statistically	O
significant	O
differences	O
between	O
the	O
CTR	O
and	O
the	O
various	O
conditions	O
,	O
using	O
GraphPad	O
Prism	O
software	O
.	O

Study	O
approval	O

Permission	O
to	O
use	O
the	O
tissues	O
from	O
the	O
FinXX	O
study	O
for	O
research	O
purposes	O
was	O
provided	O
by	O
the	O
Finnish	O
Ministry	O
of	O
Social	O
Affairs	O
and	O
Health	O
.	O

The	O
ethics	O
committee	O
at	O
the	O
Helsinki	O
University	O
Central	O
Hospital	O
(	O
Helsinki	O
,	O
Finland	O
)	O
approved	O
the	O
FinXX	O
study	O
and	O
the	O
current	O
study	O
(	O
permission	O
HUS	O
35	O
/	O
13	O
/	O
03	O
/	O
02	O
/	O
2015	O
).	O

Ethical	O
approval	O
for	O
the	O
use	O
of	O
peripheral	O
blood	O
from	O
healthy	O
donors	O
was	O
obtained	O
from	O
the	O
Nantes	O
University	O
Hospital	O
Ethics	O
Committee	O
.	O

Samples	O
were	O
obtained	O
from	O
the	O
Établissement	O
Français	O
du	O
Sang	O
with	O
informed	O
consent	O
(	O
agreement	O
reference	O
NTS	O
2000	O
–	O
24	O
,	O
Avenant	O
n	O
°	O
10	O
).	O

Online	O
supplemental	O
material	O

A	O
supplemental	O
table	O
(	O
Additional	O
file	O
1	O
)	O
and	O
supplemental	O
figures	O
(	O
Additional	O
files	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
and	O
6	O
)	O
are	O
available	O
online	O
.	O

Results	O

Clinical	O
significance	O
of	O
TAM	O
numbers	O
and	O
differentiation	O
status	O
in	O
breast	B-DS
cancer	I-DS
patients	O

To	O
explore	O
the	O
clinical	O
relevance	O
of	O
TAM	O
differentiation	O
in	O
breast	B-DS
cancer	I-DS
patients	O
,	O
we	O
evaluated	O
total	O
TAM	O
number	O
(	O
CD68	B-GP
),	O
M1	O
TAM	O
(	O
HLA	B-GP
-	I-GP
DRα	I-GP
)	O
and	O
M2	O
TAM	O
(	O
CD163	B-GP
)	O
in	O
a	O
large	O
human	B-OG
breast	B-DS
cancer	I-DS
TMA	O
cohort	O
.	O

There	O
was	O
heterogeneity	O
among	O
the	O
patients	O
in	O
the	O
expression	O
levels	O
of	O
the	O
different	O
macrophage	O
markers	O
(	O
Fig	O
.	O
1	O
).	O

M2	O
macrophage	O
number	O
,	O
identified	O
as	O
the	O
umber	O
of	O
CD163	B-GP
+	O
cells	O
,	O
was	O
strongly	O
associated	O
with	O
fast	O
proliferation	O
(	O
Ki67	B-GP
positivity	O
>	O
20	O
%),	O
poor	O
differentiation	O
(	O
grade	O
3	O
),	O
ER	B-GP
negativity	O
and	O
histological	O
ductal	O
type	O
(	O
Table	O
2	O
).	O

None	O
of	O
the	O
individual	O
markers	O
(	O
CD68	B-GP
,	O
HLA	B-GP
-	I-GP
DRα	I-GP
or	O
CD163	B-GP
)	O
was	O
on	O
its	O
own	O
strongly	O
correlated	O
with	O
prognosis	O
,	O
recurrence	O
-	O
free	O
survival	O
(	O
RFS	O
)	O
or	O
overall	O
survival	O
(	O
Additional	O
file	O
2	O
).	O

In	O
the	O
multivariate	O
Cox	O
model	O
for	O
RFS	O
,	O
markers	O
such	O
as	O
Ki67	B-GP
positivity	O
>	O
20	O
%,	O
node	O
positivity	O
and	O
primary	B-DS
tumor	I-DS
size	O
>	O
22	O
mm	O
were	O
strongly	O
significant	O
predictive	O
factors	O
(	O
p	O
<	O
0	O
.	O
001	O
for	O
tumor	B-DS
size	O
and	O
<	O
0	O
.	O
01	O
for	O
the	O
other	O
factors	O
).	O

In	O
the	O
same	O
model	O
CD163	B-GP
was	O
a	O
significant	O
factor	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
together	O
with	O
other	O
model	O
covariates	O
,	O
such	O
as	O
ER	B-GP
negativity	O
(	O
Table	O
3	O
).	O
Fig	O
.	O
1Representative	O
images	O
of	O
tissue	O
microarray	O
(	O
TMA	O
)	O
staining	O
revealing	O
interpatient	O
heterogeneous	O
macrophage	O
marker	O
expression	O
levels	O
.	O

CD68	B-GP
(	O
a	O
-	O
d	O
),	O
HLA	B-GP
-	I-GP
DRIIα	I-GP
(	O
e	O
-	O
h	O
)	O
and	O
CD163	B-GP
(	O
i	O
-	O
l	O
).	O

Patient	O
core	O
overview	O
(	O
a	O
,	O
c	O
,	O
e	O
,	O
g	O
,	O
i	O
,	O
k	O
,	O
scale	O
bars	O
200	O
μm	O
)	O
and	O
a	O
detailed	O
view	O
of	O
selected	O
area	O
(	O
b	O
,	O
d	O
,	O
f	O
,	O
h	O
,	O
j	O
,	O
l	O
,	O
scale	O
bars	O
50	O
μm	O
).	O

Objective	O
amplification	O
×	O
10Table	O
2CD68	O
+	O
and	O
CD163	B-GP
+	O
cell	O
number	O
median	O
values	O
and	O
relevant	O
clinical	O
characteristicsFactorN	O
=	O
551CD68	O
+	O
median	O
(	O
range	O
)	O
P	O
a	O
N	O
=	O
537CD163	O
+	O
median	O
(	O
range	O
)	O
P	O
a	O
Histological	O
typeDuctal392418	O
(	O
0	O
–	O
3634	O
)	O
384208	O
(	O
2	O
–	O
1772	O
)	O
Lobular109249	O
(	O
1	O
–	O
3113	O
)	O
102106	O
(	O
3	O
–	O
802	O
)	O
Other50265	O
(	O
0	O
–	O
1397	O
)<	O
0	O
.	O
00151127	O
(	O
4	O
–	O
1359	O
)<	O
0	O
.	O
001Histological	O
gradeGrade	O
146240	O
(	O
18	O
–	O
3113	O
)	O
42125	O
(	O
5	O
–	O
524	O
)	O
Grade	O
2257337	O
(	O
0	O
–	O
3634	O
)	O
250115	O
(	O
2	O
–	O
1229	O
)	O
Grade	O
3246436	O
(	O
0	O
–	O
2595	O
)<	O
0	O
.	O
001243265	O
(	O
3	O
–	O
1772	O
)<	O
0	O
.	O
001N	O
.	O
A	O
.	O
22ER	O
statusPositive396340	O
(	O
0	O
–	O
3634	O
)	O
385131	O
(	O
2	O
–	O
1772	O
)	O
Negative155435	O
(	O
0	O
–	O
2595	O
)	O
0	O
.	O
006152268	O
(	O
6	O
–	O
1743	O
)<	O
0	O
.	O
001HER	O
-	O
2	O
statusPositive168363	O
(	O
9	O
–	O
2673	O
)	O
165221	O
(	O
2	O
–	O
1772	O
)	O
Negative383369	O
(	O
0	O
–	O
3634	O
)	O
0	O
.	O
900372148	O
(	O
3	O
–	O
1359	O
)	O
0	O
.	O
002Biological	O
groupER	O
+,	O
HER	B-GP
-	I-GP
2	I-GP
−	O
307334	O
(	O
0	O
–	O
3634	O
)	O
296124	O
(	O
3	O
–	O
1359	O
)	O
ER	B-GP
+,	O
HER	B-GP
-	I-GP
2	I-GP
+	O
89343	O
(	O
12	O
–	O
2673	O
)	O
89200	O
(	O
2	O
–	O
1772	O
)	O
ER	B-GP
-,	O
HER	B-GP
-	I-GP
2	I-GP
+	O
79424	O
(	O
9	O
–	O
1306	O
.	O
5	O
)	O
76227	O
(	O
7	O
–	O
1743	O
)	O
ER	B-GP
-,	O
HER	B-GP
-	I-GP
2	I-GP
−	O
76484	O
(	O
0	O
–	O
2595	O
)	O
0	O
.	O
02376289	O
(	O
6	O
–	O
1111	O
)<	O
0	O
.	O
001Ki67	O
≤	O
20	O
%	O
265318	O
(	O
0	O
–	O
3634	O
)	O
254115	O
(	O
2	O
–	O
1772	O
)>	O
20	O
%	O
238431	O
(	O
0	O
–	O
2794	O
)	O
0	O
.	O
002236263	O
(	O
3	O
–	O
1743	O
)<	O
0	O
.	O
001N	O
.	O
A	O
.	O
4847	O
aMann	O
-	O
Whitney	O
or	O
Kruskal	O
-	O
Wallis	O
test	O
.	O
ER	B-GP
estrogen	B-GP
receptor	I-GP
,	O
HER	B-GP
-	I-GP
2	I-GP
human	B-GP
epidermal	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
2	I-GP
,	O
N	O
.	O
A	O
.	O
not	O
availableTable	O
3Independent	O
prognostic	O
factors	O
in	O
Cox	O
multivariate	O
model	O
for	O
recurrence	O
-	O
free	O
survival	O
in	O
yearsVariablesRegression	O
coefficentStandard	O
errorRegression	O
coefficient	O
/	O
standard	O
error	O
χ	O
2	O
P	O
Exp	O
(	O
Coef	O
)	O
95	O
%	O
CILowerUpperER	O
+	O
−	O
0	O
.	O
6120	O
.	O
252	O
−	O
2	O
.	O
4305	O
.	O
9030	O
.	O
01510	O
.	O
5420	O
.	O
3310	O
.	O
888HER	O
-	O
2	O
+	O
0	O
.	O
0500	O
.	O
2390	O
.	O
2110	O
.	O
0450	O
.	O
83261	O
.	O
0520	O
.	O
6591	O
.	O
679Ki67	O
>	O
20	O
%−	O
0	O
.	O
7110	O
.	O
269	O
−	O
2	O
.	O
6426	O
.	O
9810	O
.	O
00820	O
.	O
4910	O
.	O
2900	O
.	O
832Node	O
positivity	O
−	O
1	O
.	O
0960	O
.	O
394	O
−	O
2	O
.	O
7807	O
.	O
7300	O
.	O
00540	O
.	O
3340	O
.	O
1540	O
.	O
724Size	O
>	O
22	O
mm	O
−	O
0	O
.	O
8650	O
.	O
237	O
−	O
3	O
.	O
65713	O
.	O
3720	O
.	O
00030	O
.	O
4210	O
.	O
2650	O
.	O
669Histological	O
grade	O
3	O
−	O
0	O
.	O
0710	O
.	O
268	O
−	O
0	O
.	O
2660	O
.	O
0710	O
.	O
78990	O
.	O
9310	O
.	O
5501	O
.	O
575CD163	O
>	O
167	O
.	O
50	O
.	O
5800	O
.	O
2292	O
.	O
5316	O
.	O
4080	O
.	O
01141	O
.	O
7861	O
.	O
1402	O
.	O
798	O
ER	B-GP
estrogen	B-GP
receptor	I-GP
,	O
HER	B-GP
-	I-GP
2	I-GP
human	B-GP
epidermal	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
2	I-GP
,	O
Coef	O
regression	O
coefficient	O
,	O
χ	O
2	O
chi	O
-	O
squared	O
,	O
Exp	O
(	O
Coef	O
)	O
hazard	O
ratio	O

Human	B-OG
breast	B-DS
cancer	I-DS
cells	O
condition	O
ex	O
vivo	O
differentiation	O
and	O
activation	O
of	O
human	B-OG
macrophages	O

As	O
a	O
proof	O
of	O
concept	O
,	O
we	O
showed	O
that	O
the	O
isolated	O
CD14	B-GP
+	O
cells	O
could	O
be	O
differentiated	O
to	O
M1	O
(	O
high	O
CD64	B-GP
,	O
high	O
IL	B-GP
-	I-GP
6	I-GP
secretion	O
),	O
M2a	O
(	O
high	O
CD200R	B-GP
and	O
CD86	B-GP
,	O
low	O
IL	B-GP
-	I-GP
6	I-GP
and	O
high	O
IL	B-GP
-	I-GP
8	I-GP
secretion	O
)	O
and	O
M2c	O
macrophages	O
(	O
high	O
CD163	B-GP
,	O
low	O
IL	B-GP
-	I-GP
6	I-GP
and	O
high	O
IL	B-GP
-	I-GP
10	I-GP
secretion	O
),	O
respectively	O
,	O
using	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
,	O
thus	O
,	O
demonstrating	O
their	O
proven	O
[	O
34	O
]	O
ex	O
vivo	O
plasticity	O
(	O
Figs	O
.	O
2	O
,	O
3	O
and	O
4	O
and	O
Additional	O
file	O
3	O
).	O

Considering	O
M1	O
differentiation	O
in	O
the	O
presence	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
none	O
of	O
the	O
CM	O
affected	O
the	O
expression	O
levels	O
of	O
M1	O
surface	O
-	O
markers	O
(	O
Additional	O
file	O
4	O
)	O
nor	O
the	O
secretion	O
profile	O
(	O
data	O
not	O
shown	O
).	O
Fig	O
.	O
2Flow	O
cytometry	O
analysis	O
of	O
CD14	B-GP
+	O
cells	O
differentiated	O
for	O
5	O
days	O
with	O
or	O
without	O
50	O
%	O
conditioned	O
media	O
(	O
CM	O
).	O
a	O
-	O
e	O
Percentual	O
variation	O
of	O
median	O
fluorescence	O
intensity	O
(	O
MedFI	O
)	O
of	O
CD14	B-GP
,	O
CD16	B-GP
,	O
CD86	B-GP
,	O
CD200R	B-GP
and	O
CD163	B-GP
compared	O
to	O
control	O
(	O
CTR	O
),	O
n	O
=	O
5	O
.	O
f	O
Monocyte	B-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
(	O
M	B-GP
-	I-GP
CSF	I-GP
)	O
protein	O
levels	O
in	O
breast	B-DS
cancer	I-DS
cell	O
line	O
CM	O
(	O
n	O
=	O
3	O
).	O
g	O
-	O
i	O
Flow	O
cytometry	O
analysis	O
of	O
CD14	B-GP
+	O
cells	O
differentiated	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
10	I-GP
for	O
5	O
days	O
with	O
or	O
without	O
50	O
%	O
breast	B-DS
cancer	I-DS
cell	O
line	O
CM	O
.	O

Percent	O
variation	O
of	O
MedFI	O
of	O
CD14	B-GP
,	O
CD16	B-GP
and	O
CD163	B-GP
compared	O
to	O
CTR	O
(	O
IL	B-GP
-	I-GP
10	I-GP
alone	O
).	O
Error	O
bars	O
represent	O
+	O
SD	O
,	O
n	O
=	O
5	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
005	O
(	O
Kruskal	O
-	O
Wallis	O
analysis	O
followed	O
by	O
Dunn	O
’	O
s	O
post	O
hoc	O
test	O
).	O
MB231	O
,	O
MDA	O
-	O
MB231	O
CMFig	O
.	O
3Cytokine	O
secretion	O
profile	O
after	O
24	O
h	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
stimulation	O
.	O
a	O
-	O
c	O
CD14	B-GP
+	O
cells	O
differentiated	O
for	O
5	O
days	O
with	O
or	O
without	O
50	O
%	O
breast	B-DS
cancer	I-DS
cell	O
line	O
conditioned	O
media	O
(	O
CM	O
)	O
(	O
d	O
-	O
f	O
)	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
4	I-GP
(	O
g	O
-	O
i	O
)	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
10	I-GP
.	O
a	O
-	O
i	O
All	O
results	O
are	O
the	O
mean	O
of	O
three	O
experimental	O
replicates	O
and	O
two	O
biological	O
replicates	O
.	O
j	O
Representative	O
matrix	B-GP
metalloproteinase	I-GP
(	B-GP
MMP	I-GP
)-	I-GP
9	I-GP
zymography	O
gel	O
(	O
k	O
)	O
relative	O
MMP	B-GP
-	I-GP
9	I-GP
activity	O
,	O
expressed	O
as	O
digested	O
band	O
optical	O
density	O
normalized	O
to	O
equivalent	O
background	O
area	O
optical	O
density	O
.	O
Error	O
bars	O
represent	O
+	O
SD	O
,	O
n	O
=	O
3	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
005	O
,	O
***	O
p	O
<	O
0	O
.	O
0005	O
(	O
Kruskal	O
-	O
Wallis	O
analysis	O
followed	O
by	O
Dunn	O
’	O
s	O
post	O
hoc	O
test	O
).	O
MB231	O
,	O
MDA	O
-	O
MB231	O
CM	O
;	O
NT	O
,	O
non	O
-	O
treatedFig	O
.	O
4Flow	O
cytometry	O
analysis	O
of	O
CD14	B-GP
+	O
cells	O
differentiated	O
for	O
5	O
days	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
4	I-GP
with	O
or	O
without	O
50	O
%	O
conditioned	O
media	O
(	O
CM	O
).	O
a	O
CD14loCD16lo	O
and	O
CD14hiCD16hi	O
subpopulation	O
distribution	O
.	O
b	O
,	O
d	O
,	O
f	O
,	O
h	O
,	O
j	O
Overall	O
percent	O
variation	O
of	O
CD14	B-GP
,	O
CD16	B-GP
,	O
CD163	B-GP
,	O
CD200R	B-GP
and	O
CD86	B-GP
median	O
fluorescence	O
intensity	O
(	O
MedFI	O
),	O
compared	O
with	O
control	O
(	O
CTR	O
)	O
(	O
IL	B-GP
-	I-GP
4	I-GP
alone	O
)	O
(	O
c	O
,	O
e	O
,	O
g	O
,	O
i	O
,	O
k	O
)	O
CD14	B-GP
CD16	B-GP
,	O
CD163	B-GP
,	O
CD200R	B-GP
and	O
CD86	B-GP
MedFI	O
percent	O
variation	O
in	O
the	O
subpopulations	O
CD14loCD16lo	O
and	O
CD14hiCD16hi	O
.	O
Error	O
bars	O
represent	O
+	O
SD	O
,	O
n	O
=	O
5	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
005	O
,	O
***	O
p	O
<	O
0	O
.	O
0005	O
(	O
Kruskal	O
-	O
Wallis	O
analysis	O
followed	O
by	O
Dunn	O
’	O
s	O
post	O
hoc	O
test	O
).	O
MB231	O
,	O
MDA	O
-	O
MB231	O
CM	O

CD14	B-GP
+	O
cells	O
differentiated	O
in	O
the	O
presence	O
of	O
MDA	O
-	O
MB231	O
CM	O
alone	O
yielded	O
an	O
M2	O
macrophage	O
population	O
(	O
Fig	O
.	O
2a	O
-	O
e	O
).	O

This	O
result	O
was	O
most	O
obvious	O
in	O
terms	O
of	O
CD86	B-GP
,	O
CD200R	B-GP
and	O
CD163	B-GP
expression	O
levels	O
(	O
Fig	O
.	O
2c	O
-	O
e	O
).	O

The	O
differentiation	O
only	O
in	O
the	O
presence	O
of	O
other	O
CM	O
retained	O
the	O
control	O
phenotype	O
features	O
(	O
Fig	O
.	O
2a	O
-	O
e	O
and	O
Additional	O
file	O
3	O
).	O

Macrophages	O
differentiated	O
in	O
the	O
presence	O
of	O
MDA	O
-	O
MB231	O
CM	O
produced	O
higher	O
amounts	O
of	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
(	O
Fig	O
.	O
3a	O
-	O
c	O
)	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
(	O
Fig	O
.	O
3j	O
-	O
k	O
)	O
than	O
the	O
CTR	O
or	O
other	O
CM	O
.	O

That	O
scenario	O
remained	O
true	O
when	O
the	O
cells	O
were	O
concomitantly	O
treated	O
with	O
IL	B-GP
-	I-GP
4	I-GP
(	O
Fig	O
.	O
3d	O
-	O
f	O
)	O
or	O
IL	B-GP
-	I-GP
10	I-GP
(	O
Fig	O
.	O
3g	O
-	O
i	O
),	O
except	O
for	O
IL	B-GP
-	I-GP
6	I-GP
secretion	O
in	O
the	O
latter	O
treatment	O
(	O
Fig	O
.	O
3g	O
).	O

MDA	O
-	O
MB231	O
cells	O
secrete	O
large	O
amounts	O
of	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
skewing	O
macrophages	O
to	O
an	O
M2c	O
-	O
like	O
phenotype	O

The	O
strong	O
effects	O
of	O
the	O
MDA	O
-	O
MB231	O
cells	O
led	O
us	O
to	O
inspect	O
all	O
the	O
CM	O
for	O
dissimilarly	O
secreted	O
macrophage	O
-	O
differentiating	O
factors	O
.	O

We	O
saw	O
no	O
differences	O
in	O
terms	O
of	O
IL	B-GP
-	I-GP
10	I-GP
,	O
transforming	B-GP
growth	I-GP
factor	I-GP
(	I-GP
TGF	I-GP
)-	I-GP
β	I-GP
or	O
IL	B-GP
-	I-GP
4	I-GP
(	O
data	O
not	O
shown	O
),	O
but	O
only	O
MDA	O
-	O
MB231	O
cells	O
secreted	O
high	O
amounts	O
of	O
M	B-GP
-	I-GP
CSF	I-GP
(	O
Fig	O
.	O
2f	O
).	O

CD14	B-GP
+	O
cells	O
differentiated	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
10	I-GP
and	O
MDA	O
-	O
MB231	O
or	O
T47D	O
CM	O
(	O
Fig	O
.	O
2g	O
-	O
i	O
and	O
Additional	O
file	O
5	O
)	O
showed	O
a	O
decrease	O
in	O
CD14	B-GP
expression	O
levels	O
when	O
compared	O
to	O
cells	O
differentiated	O
only	O
with	O
IL	B-GP
-	I-GP
10	I-GP
(	O
CTR	O
,	O
Fig	O
.	O
2g	O
).	O

MDA	O
-	O
MB231	O
CM	O
significantly	O
increased	O
CD163	B-GP
expression	O
levels	O
(	O
Fig	O
.	O
2i	O
).	O

The	O
macrophages	O
treated	O
with	O
IL	B-GP
-	I-GP
10	I-GP
and	O
MDA	O
-	O
MB231	O
CM	O
secreted	O
more	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
and	O
MMP	B-GP
-	I-GP
9	I-GP
than	O
the	O
CTR	O
IL	B-GP
-	I-GP
10	I-GP
-	O
treated	O
macrophages	O
(	O
Fig	O
.	O
3g	O
-	O
k	O
).	O

Human	B-OG
breast	B-DS
cancer	I-DS
cells	O
affect	O
M2a	O
macrophage	O
differentiation	O
,	O
rendering	O
macrophages	O
to	O
a	O
mixed	O
M2a	O
/	O
M2c	O
phenotype	O

When	O
exposed	O
to	O
IL	B-GP
-	I-GP
4	I-GP
,	O
two	O
major	O
macrophage	O
subpopulations	O
arose	O
in	O
all	O
the	O
conditions	O
:	O
CD14lo	O
/	O
C16lo	O
and	O
CD14hi	O
/	O
CD16hi	O
(	O
Fig	O
.	O
4	O
).	O

In	O
the	O
presence	O
of	O
breast	B-DS
cancer	I-DS
cell	O
line	O
CM	O
,	O
the	O
relative	O
percentage	O
of	O
each	O
of	O
these	O
subpopulations	O
changed	O
.	O

Instead	O
of	O
a	O
predominance	O
of	O
the	O
CD14lo	O
/	O
C16lo	O
population	O
(	O
CTR	O
,	O
Fig	O
.	O
4a	O
),	O
there	O
was	O
a	O
statistically	O
significant	O
inversion	O
toward	O
a	O
predominance	O
of	O
the	O
CD14hi	O
/	O
CD16hi	O
population	O
(	O
Fig	O
.	O
4a	O
),	O
especially	O
in	O
the	O
presence	O
of	O
MDA	O
-	O
MB231	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
or	O
T47D	O
CM	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

MCF	O
-	O
7	O
CM	O
showed	O
the	O
same	O
trend	O
reaching	O
equilibrium	O
between	O
the	O
two	O
subpopulations	O
not	O
significantly	O
statistically	O
different	O
from	O
the	O
subpopulation	O
distribution	O
in	O
the	O
CTR	O
(	O
IL	B-GP
-	I-GP
4	I-GP
alone	O
).	O

The	O
detailed	O
analysis	O
of	O
the	O
surface	O
-	O
markers	O
from	O
those	O
subpopulations	O
indicated	O
that	O
MDA	O
-	O
MB231	O
and	O
T47D	O
CM	O
increase	O
CD14	B-GP
(	O
Fig	O
.	O
4b	O
)	O
and	O
decrease	O
CD86	B-GP
overall	O
expression	O
(	O
Fig	O
.	O
4j	O
).	O

MDA	O
-	O
MB231	O
CM	O
increases	O
CD16	B-GP
(	O
Fig	O
.	O
4d	O
),	O
CD163	B-GP
(	O
Fig	O
.	O
4f	O
)	O
and	O
CD200R	B-GP
expression	O
(	O
Fig	O
.	O
4h	O
).	O

These	O
fluctuations	O
are	O
mostly	O
due	O
to	O
the	O
CD14hi	O
/	O
CD16hi	O
population	O
(	O
Fig	O
.	O
4c	O
,	O
e	O
,	O
g	O
,	O
i	O
,	O
k	O
)	O
and	O
the	O
results	O
were	O
statistically	O
significant	O
for	O
the	O
global	O
expression	O
(	O
Fig	O
.	O
4b	O
,	O
d	O
,	O
f	O
,	O
h	O
,	O
j	O
;	O
p	O
<	O
0	O
.	O
05	O
).	O

Although	O
not	O
statistically	O
significant	O
,	O
MCF	O
-	O
7	O
CM	O
induced	O
the	O
same	O
trend	O
as	O
T47D	O
CM	O
(	O
Fig	O
.	O
4a	O
-	O
k	O
).	O

Only	O
MDA	O
-	O
MB231	O
CM	O
affected	O
cytokine	B-GP
and	O
MMP	B-GP
-	I-GP
9	I-GP
secretion	O
,	O
reflecting	O
the	O
exceptionality	O
of	O
this	O
cell	O
line	O
(	O
Fig	O
.	O
3d	O
-	O
f	O
,	O
j	O
,	O
k	O
).	O

MDA	O
-	O
MB231	O
CM	O
in	O
the	O
IL	B-GP
-	I-GP
4	I-GP
condition	O
increased	O
IL	B-GP
-	I-GP
10	I-GP
secretion	O
(	O
Fig	O
.	O
3f	O
),	O
and	O
increased	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
(	O
Fig	O
.	O
3d	O
,	O
e	O
)	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
secretion	O
(	O
Fig	O
.	O
3j	O
,	O
k	O
).	O

If	O
compared	O
to	O
MDA	O
-	O
MB231	O
CM	O
alone	O
,	O
IL	B-GP
-	I-GP
4	I-GP
combined	O
with	O
MDA	O
-	O
MB231	O
CM	O
decreased	O
the	O
secretion	O
of	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
and	O
MMP	B-GP
-	I-GP
9	I-GP
and	O
increased	O
IL	B-GP
-	I-GP
10	I-GP
secretion	O
(	O
Fig	O
.	O
3a	O
-	O
c	O
and	O
Fig	O
.	O
3j	O
,	O
k	O
).	O

Overall	O
,	O
MDA	O
-	O
MB231	O
CM	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
4	I-GP
produced	O
a	O
macrophage	O
subpopulation	O
with	O
an	O
intermediate	O
/	O
mixed	O
M2a	O
/	O
M2c	O
phenotype	O
(	O
Additional	O
file	O
6	O
),	O
with	O
an	O
abundant	O
production	O
of	O
the	O
immunosuppressive	O
M2c	O
-	O
inducing	O
cytokine	B-GP
IL	B-GP
-	I-GP
10	I-GP
.	O

These	O
macrophages	O
retain	O
matrix	O
-	O
remodeling	O
properties	O
by	O
secreting	O
MMP	B-GP
-	I-GP
9	I-GP
.	O

The	O
possibility	O
that	O
the	O
MCF	O
-	O
7	O
or	O
T47D	O
CM	O
-	O
induced	O
CD14hi	O
/	O
CD16hi	O
macrophage	O
subpopulations	O
also	O
secrete	O
different	O
levels	O
of	O
cytokines	B-GP
should	O
not	O
be	O
discarded	O
.	O

Those	O
more	O
subtle	O
differences	O
may	O
be	O
masked	O
by	O
the	O
higher	O
titers	O
produced	O
by	O
the	O
MDA	O
-	O
MB231	O
-	O
CM	O
-	O
induced	O
CD14hi	O
/	O
CD16hi	O
subpopulations	O
.	O

Discussion	O

Clinical	O
significance	O
of	O
TAM	O
numbers	O
and	O
differentiation	O
status	O
in	O
breast	B-DS
cancer	I-DS
patients	O

In	O
this	O
study	O
CD163	B-GP
+	O
cells	O
in	O
primary	O
breast	B-DS
tumor	I-DS
tissue	O
were	O
brought	O
up	O
as	O
a	O
negative	O
prognosis	O
factor	O
for	O
RFS	O
.	O

However	O
,	O
we	O
could	O
not	O
precisely	O
determine	O
which	O
would	O
be	O
the	O
additional	O
interacting	O
factors	O
involved	O
in	O
this	O
effect	O
.	O

It	O
is	O
clear	O
that	O
CD163	B-GP
correlates	O
with	O
known	O
factors	O
to	O
be	O
associated	O
with	O
a	O
bad	O
prognosis	O
,	O
such	O
as	O
ER	B-GP
negativity	O
,	O
poor	O
differentiation	O
(	O
grade	O
3	O
)	O
and	O
ductal	O
type	O
(	O
Tables	O
1	O
and	O
2	O
).	O

Previous	O
studies	O
have	O
shown	O
that	O
higher	O
tumor	B-DS
grade	O
[	O
22	O
]	O
and	O
higher	O
Ki67	B-GP
index	O
are	O
associated	O
with	O
increased	O
CD68	B-GP
+	O
macrophage	O
infiltration	O
in	O
breast	B-DS
tumors	I-DS
[	O
23	O
,	O
35	O
].	O

It	O
was	O
suggested	O
that	O
highly	O
proliferative	O
high	O
-	O
grade	O
tumors	B-DS
elicit	O
an	O
active	O
immune	O
response	O
that	O
further	O
supports	O
angiogenesis	O
and	O
tumor	B-DS
growth	O
.	O

Further	O
,	O
these	O
high	O
-	O
grade	O
tumors	B-DS
may	O
secrete	O
higher	O
levels	O
of	O
macrophage	O
-	O
recruiting	O
/	O
modulating	O
cytokines	B-GP
such	O
as	O
M	B-GP
-	I-GP
CSF	I-GP
(	O
ex	O
vivo	O
results	O
,	O
Fig	O
.	O
2f	O
),	O
IL	B-GP
-	I-GP
10	I-GP
and	O
/	O
or	O
TGF	B-GP
-	I-GP
β	I-GP
[	O
6	O
],	O
which	O
is	O
in	O
agreement	O
with	O
the	O
high	O
number	O
of	O
CD163	B-GP
+	O
M2	O
-	O
macrophages	O
.	O

A	O
study	O
exploring	O
stromal	O
gene	O
signatures	O
in	O
DCIS	B-DS
and	O
invasive	B-DS
breast	I-DS
cancer	I-DS
found	O
that	O
higher	O
grade	O
ER	B-GP
-	O
negative	O
and	O
PR	O
-	O
negative	O
tumors	B-DS
are	O
associated	O
with	O
macrophage	O
responses	O
[	O
36	O
].	O

Macrophage	O
infiltration	O
was	O
present	O
early	O
in	O
the	O
tumor	B-DS
progression	O
at	O
the	O
DCIS	B-DS
stage	O
,	O
and	O
the	O
majority	O
of	O
cases	O
remained	O
positive	O
in	O
matched	O
invasive	B-DS
breast	I-DS
cancer	I-DS
cases	O
,	O
accounting	O
for	O
early	O
macrophage	O
recruitment	O
in	O
breast	B-DS
cancer	I-DS
progression	O
[	O
36	O
].	O

Although	O
widely	O
accepted	O
as	O
a	O
specific	O
monocyte	O
/	O
macrophage	O
marker	O
,	O
CD163	B-GP
can	O
also	O
be	O
expressed	O
by	O
immature	O
MDCs	O
,	O
which	O
include	O
myeloid	O
-	O
derived	O
suppressor	O
cells	O
(	O
MDSCs	O
),	O
known	O
to	O
favor	O
tumor	B-DS
progression	O
[	O
24	O
].	O

Therefore	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
a	O
percentage	O
of	O
the	O
CD163	B-GP
+	O
cells	O
detected	O
may	O
in	O
fact	O
be	O
MDSCs	O
,	O
which	O
could	O
account	O
for	O
the	O
poor	O
prognostic	O
role	O
of	O
CD163	B-GP
.	O

Differential	O
ex	O
vivo	O
conditioning	O
of	O
human	B-OG
macrophage	O
differentiation	O
and	O
activation	O
by	O
different	O
breast	B-DS
cancer	I-DS
cell	O
types	O

Levano	O
et	O
al	O
.	O
[	O
7	O
]	O
explored	O
the	O
cytokine	B-GP
receptor	I-GP
profile	O
of	O
different	O
breast	B-DS
cancer	I-DS
cell	O
types	O
and	O
found	O
that	O
basal	O
-	O
like	O
cells	O
(	O
e	O
.	O
g	O
.,	O
MDA	O
-	O
MB231	O
)	O
express	O
preferentially	O
granulocyte	B-GP
monocyte	I-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
(	O
GM	B-GP
-	I-GP
CSF	I-GP
),	O
hepatocyte	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
(	O
HGFR	B-GP
,	O
also	O
known	O
as	O
c	B-GP
-	I-GP
MET	I-GP
),	O
CD44	B-GP
,	O
epithelial	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
(	O
EGFR	B-GP
),	O
transforming	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
2	I-GP
(	O
TGFR2	B-GP
)	O
and	O
oncostatin	B-GP
M	I-GP
receptor	I-GP
(	O
OSMR	B-GP
).	O

Luminal	O
-	O
type	O
breast	B-DS
cancer	I-DS
cells	O
(	O
e	O
.	O
g	O
.,	O
MCF	O
-	O
7	O
and	O
T47D	O
)	O
express	O
RET	B-GP
(	O
a	O
proto	O
-	O
oncogene	O
which	O
encodes	O
for	O
a	O
receptor	B-GP
tyrosine	I-GP
kinase	I-GP
for	O
members	O
of	O
the	O
glial	B-GP
cell	I-GP
line	I-GP
-	I-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
)	O
[	O
7	O
]	O
and	O
leukemia	B-GP
inhibitory	I-GP
factor	I-GP
(	O
LIF	B-GP
)	O
[	O
37	O
].	O

This	O
suggests	O
that	O
TAMs	O
have	O
a	O
different	O
influence	O
depending	O
on	O
the	O
tumor	B-DS
subtype	O
,	O
as	O
breast	B-DS
cancer	I-DS
cells	O
will	O
have	O
different	O
receptors	O
for	O
TAM	O
-	O
derived	O
factors	O
[	O
7	O
].	O

Further	O
,	O
mesenchymal	O
or	O
epithelial	O
-	O
like	O
breast	B-DS
cancer	I-DS
cells	O
respond	O
to	O
or	O
influence	O
TAMs	O
differently	O
.	O

It	O
has	O
been	O
shown	O
that	O
mesenchymal	O
-	O
like	O
breast	B-DS
cancer	I-DS
cells	O
secrete	O
GM	B-GP
-	I-GP
CSF	I-GP
to	O
activate	O
macrophages	O
to	O
a	O
CCL18	B-GP
-	O
expressing	O
TAM	O
-	O
like	O
phenotype	O
and	O
,	O
reciprocally	O
,	O
these	O
TAM	O
-	O
like	O
macrophages	O
sustain	O
the	O
EMT	O
of	O
cancer	B-DS
cells	O
[	O
38	O
].	O

These	O
findings	O
are	O
not	O
totally	O
unexpected	O
when	O
considering	O
the	O
role	O
of	O
macrophages	O
in	O
mammary	O
gland	O
development	O
during	O
embryogenesis	O
,	O
puberty	O
,	O
pregnancy	O
and	O
lactation	O
.	O

Macrophages	O
in	O
the	O
mammary	O
gland	O
were	O
proven	O
essential	O
in	O
supporting	O
and	O
activating	O
mammary	O
stem	O
cells	O
necessary	O
for	O
normal	O
morphogenesis	O
[	O
39	O
],	O
branching	O
[	O
9	O
]	O
and	O
in	O
the	O
postpartum	O
-	O
related	O
influx	O
of	O
M2	O
macrophages	O
[	O
10	O
].	O

All	O
these	O
developmental	O
processes	O
occur	O
via	O
mechanisms	O
similar	O
to	O
molecular	O
cancer	B-DS
mechanisms	O
,	O
such	O
as	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
A	I-GP
(	O
VEGF	B-GP
-	I-GP
A	I-GP
)-	O
stimulated	O
angiogenesis	O
.	O

Additionally	O
,	O
TAMs	O
secrete	O
EGF	B-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
VEGF	B-GP
and	O
basic	B-GP
fibroblast	I-GP
growth	I-GP
factor	I-GP
(	O
bFGF	B-GP
)	O
and	O
have	O
reduced	O
antigen	O
presenting	O
ability	O
.	O

Also	O
the	O
release	O
of	O
IL	B-GP
-	I-GP
10	I-GP
by	O
both	O
tumor	B-DS
cells	O
and	O
TAMs	O
immunosuppresses	O
cytotoxic	O
T	O
-	O
lymphocytes	O
(	O
CTLs	O
)	O
[	O
9	O
].	O

A	O
study	O
of	O
murine	B-OG
and	O
human	B-OG
macrophage	O
polarization	O
profiles	O
showed	O
that	O
M	B-GP
-	I-GP
CSF	I-GP
-	O
differentiated	O
human	B-OG
macrophages	O
are	O
pro	O
-	O
M2	O
,	O
meaning	O
that	O
LPS	O
or	O
IFN	B-GP
-	I-GP
γ	I-GP
stimulation	O
can	O
still	O
induce	O
an	O
M1	O
response	O
.	O

However	O
,	O
if	O
stimulated	O
with	O
IL	B-GP
-	I-GP
4	I-GP
or	O
IL	B-GP
-	I-GP
10	I-GP
they	O
become	O
more	O
M2	O
type	O
than	O
the	O
basal	O
macrophages	O
[	O
40	O
].	O

M	B-GP
-	I-GP
CSF	I-GP
induces	O
CD163	B-GP
expression	O
in	O
macrophages	O
which	O
,	O
when	O
LPS	O
-	O
stimulated	O
,	O
secrete	O
higher	O
levels	O
of	O
IL	B-GP
-	I-GP
12p40	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
[	O
34	O
].	O

Our	O
MDA	O
-	O
MB231	O
cells	O
produce	O
copious	O
amounts	O
of	O
M	B-GP
-	I-GP
CSF	I-GP
(	O
Fig	O
.	O
2f	O
),	O
in	O
levels	O
similar	O
to	O
clinical	O
samples	O
and	O
MDA	O
-	O
MB231	O
cells	O
,	O
as	O
reported	O
previously	O
[	O
6	O
].	O

Similarly	O
,	O
the	O
monocyte	O
shift	O
toward	O
M2	O
/	O
CD163	B-GP
+	O
TAMs	O
by	O
increased	O
levels	O
of	O
M	B-GP
-	I-GP
CSF	I-GP
has	O
been	O
seen	O
in	O
other	O
tumor	B-DS
types	O
such	O
as	O
glioma	B-DS
[	O
41	O
],	O
clear	B-DS
cell	I-DS
renal	I-DS
carcinoma	I-DS
[	O
42	O
],	O
ovarian	B-DS
carcinoma	I-DS
[	O
43	O
]	O
and	O
a	O
mouse	B-OG
model	O
of	O
osteosarcoma	B-DS
[	O
44	O
].	O

In	O
those	O
tumor	B-DS
types	O
,	O
the	O
elevated	O
M	B-GP
-	I-GP
CSF	I-GP
and	O
CD163	B-GP
expression	O
correlates	O
with	O
higher	O
tumor	B-DS
grade	O
[	O
41	O
,	O
42	O
].	O

CD163	B-GP
is	O
a	O
monocyte	B-GP
/	I-GP
macrophage	I-GP
-	I-GP
restricted	I-GP
scavenger	I-GP
receptor	I-GP
.	O

It	O
clears	O
hemoglobin	B-GP
/	O
haptoglobin	B-GP
complexes	O
,	O
hence	O
protecting	O
tissues	O
from	O
hemoglobin	B-GP
-	O
induced	O
oxidative	O
damage	O
[	O
45	O
].	O

It	O
was	O
recently	O
shown	O
that	O
breast	B-DS
cancer	I-DS
CD163	B-GP
+	O
TAMs	O
correlate	O
with	O
Wnt5a	B-GP
expression	O
,	O
the	O
latter	O
factor	O
being	O
responsible	O
for	O
macrophage	O
reprogramming	O
to	O
an	O
anti	O
-	O
inflammatory	O
M2	O
status	O
.	O

The	O
same	O
group	O
has	O
reported	O
that	O
Wnt5a	B-GP
acts	O
as	O
a	O
feedback	O
antagonist	O
of	O
toll	B-GP
-	I-GP
like	I-GP
receptor	I-GP
(	O
TLR	B-GP
)	O
signaling	O
,	O
inducing	O
IL	B-GP
-	I-GP
10	I-GP
secretion	O
[	O
26	O
].	O

Our	O
results	O
fit	O
this	O
mechanism	O
well	O
,	O
as	O
MDA	O
-	O
MB231	O
CM	O
induced	O
CD163	B-GP
expression	O
,	O
a	O
feature	O
of	O
M2c	O
TAMs	O
.	O

This	O
could	O
indicate	O
a	O
parallel	O
increase	O
in	O
Wnt5a	B-GP
that	O
inhibits	O
TLR	B-GP
response	O
and	O
increases	O
IL	B-GP
-	I-GP
10	I-GP
secretion	O
upon	O
LPS	O
stimulation	O
(	O
Fig	O
.	O
3c	O
,	O
f	O
,	O
i	O
).	O

As	O
previously	O
discussed	O
,	O
the	O
M2c	O
-	O
boosted	O
differentiation	O
by	O
MDA	O
-	O
MB231	O
-	O
secreted	O
products	O
may	O
have	O
consequences	O
in	O
terms	O
of	O
microenvironment	O
-	O
aided	O
tumor	B-DS
progression	O
via	O
immunosuppressive	O
,	O
matrix	O
remodeling	O
and	O
scavenging	O
TAM	O
functions	O
.	O

These	O
effects	O
may	O
impair	O
an	O
effective	O
immune	O
tumor	B-DS
rejection	O
as	O
our	O
in	O
vitro	O
findings	O
with	O
murine	B-OG
macrophages	O
and	O
breast	B-DS
cancer	I-DS
cell	O
line	O
CM	O
indicate	O
[	O
46	O
].	O

The	O
overall	O
decrease	O
of	O
CD86	B-GP
expression	O
in	O
M2a	O
macrophages	O
by	O
breast	B-DS
cancer	I-DS
CM	O
may	O
contribute	O
to	O
immunosuppressive	O
,	O
tumor	B-DS
-	O
promoting	O
behavior	O
.	O

CD86	B-GP
,	O
also	O
known	O
as	O
B7	B-GP
-	I-GP
2	I-GP
,	O
is	O
a	O
type	B-GP
I	I-GP
transmembrane	I-GP
protein	I-GP
of	O
the	O
immunoglobulin	B-GP
superfamily	O
.	O

It	O
is	O
a	O
co	O
-	O
stimulatory	O
molecule	O
expressed	O
by	O
antigen	O
-	O
presenting	O
cells	O
such	O
as	O
dendritic	O
cells	O
and	O
macrophages	O
.	O

Its	O
binding	O
to	O
CD28	B-GP
on	O
naïve	O
T	O
-	O
cells	O
is	O
essential	O
for	O
Th2	O
differentiation	O
,	O
cytokine	B-GP
secretion	O
and	O
induction	O
of	O
effector	O
function	O
[	O
47	O
].	O

In	O
our	O
system	O
,	O
M2a	O
macrophages	O
differentiated	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
4	I-GP
and	O
MDA	O
-	O
MB231	O
CM	O
had	O
the	O
potential	O
for	O
increased	O
CD200R	B-GP
signaling	O
which	O
in	O
vivo	O
would	O
indicate	O
an	O
immunosuppressive	O
tumor	B-DS
-	O
promoting	O
environment	O
.	O

CD200R	B-GP
is	O
a	O
myeloid	O
receptor	O
expressed	O
on	O
macrophages	O
,	O
granulocytes	O
,	O
dendritic	O
cells	O
and	O
NK	O
(	O
natural	O
killer	O
)	O
cells	O
[	O
48	O
].	O

CD200R	B-GP
signaling	O
is	O
known	O
to	O
increase	O
the	O
immune	O
activation	O
threshold	O
,	O
being	O
physiologically	O
relevant	O
in	O
restraining	O
inflammation	O
[	O
48	O
].	O

CD200	B-GP
ligand	O
interaction	O
with	O
its	O
receptor	O
CD200R	B-GP
on	O
macrophages	O
decreases	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
secretion	O
[	O
49	O
].	O

CD200	B-GP
is	O
expressed	O
by	O
cancer	B-DS
cells	O
and	O
other	O
cell	O
types	O
like	O
mesenchymal	O
stem	O
cells	O
,	O
thymocytes	O
,	O
activated	O
T	O
cells	O
,	O
B	O
cells	O
and	O
dendritic	O
cells	O
.	O

Studies	O
in	O
different	O
tumor	B-DS
types	O
,	O
including	O
breast	B-DS
cancer	I-DS
,	O
showed	O
that	O
CD200	B-GP
-	O
CD200R	B-GP
interaction	O
delivers	O
an	O
immunosuppressive	O
signal	O
.	O

This	O
signal	O
directly	O
decreases	O
inflammatory	B-GP
cytokine	I-GP
secretion	O
by	O
macrophages	O
,	O
and	O
indirectly	O
increases	O
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
and	O
decreases	O
effector	O
T	O
-	O
cell	O
numbers	O
,	O
thereby	O
promoting	O
tumor	B-DS
progression	O
by	O
immune	O
evasion	O
[	O
50	O
].	O

Limitations	O
of	O
the	O
study	O

In	O
the	O
TMA	O
analysis	O
the	O
median	O
of	O
positive	O
cells	O
for	O
each	O
marker	O
in	O
all	O
samples	O
was	O
used	O
as	O
a	O
cutoff	O
value	O
and	O
analysis	O
of	O
normal	O
breast	O
tissue	O
-	O
probably	O
carrying	O
resting	O
macrophages	O
as	O
a	O
healthy	O
baseline	O
control	O
-	O
could	O
not	O
be	O
included	O
.	O

However	O
,	O
our	O
study	O
brought	O
up	O
differences	O
in	O
TAM	O
activation	O
status	O
between	O
patients	O
relevant	O
to	O
the	O
disease	O
outcome	O
.	O

Larger	O
studies	O
are	O
thus	O
justified	O
to	O
ascertain	O
the	O
exact	O
role	O
of	O
M2	O
macrophages	O
in	O
disease	O
progression	O
.	O

In	O
the	O
ex	O
vivo	O
macrophage	O
differentiation	O
studies	O
,	O
the	O
extrapolation	O
of	O
the	O
MDA	O
-	O
MB231	O
CM	O
effects	O
on	O
macrophage	O
differentiation	O
to	O
the	O
clinical	O
situation	O
of	O
triple	B-DS
-	I-DS
negative	I-DS
breast	I-DS
cancer	I-DS
patients	O
should	O
be	O
made	O
with	O
care	O
.	O

MDA	O
-	O
MB231	O
is	O
an	O
aggressive	O
model	O
cell	O
line	O
,	O
relevant	O
in	O
the	O
field	O
as	O
it	O
is	O
the	O
parental	O
cell	O
line	O
for	O
several	O
metastatic	O
sub	O
-	O
clones	O
widely	O
used	O
in	O
experiments	O
in	O
vivo	O
[	O
51	O
–	O
53	O
].	O

The	O
MDA	O
-	O
MB231	O
cell	O
line	O
belongs	O
to	O
the	O
mesenchymal	O
-	O
like	O
subtype	O
,	O
while	O
cancer	B-DS
cells	O
from	O
triple	B-DS
-	I-DS
negative	I-DS
breast	I-DS
tumors	I-DS
,	O
which	O
can	O
be	O
of	O
seven	O
different	O
subtypes	O
,	O
have	O
phenotypic	O
diversity	O
from	O
epithelial	O
to	O
mesenchymal	O
characters	O
[	O
54	O
].	O

However	O
,	O
we	O
think	O
our	O
study	O
remains	O
relevant	O
as	O
it	O
shows	O
that	O
breast	B-DS
cancer	I-DS
cells	O
,	O
regardless	O
of	O
their	O
hormone	B-GP
receptor	I-GP
status	O
and	O
epithelial	O
/	O
mesenchymal	O
nature	O
,	O
secrete	O
factors	O
that	O
educate	O
macrophages	O
toward	O
M2	O
differentiation	O
.	O

The	O
most	O
aggressive	O
one	O
,	O
MDA	O
-	O
MB231	O
,	O
did	O
it	O
most	O
effectively	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
unveil	O
the	O
factors	O
responsible	O
for	O
the	O
effects	O
seen	O
.	O

M	B-GP
-	I-GP
CSF	I-GP
appears	O
to	O
be	O
a	O
key	O
factor	O
in	O
M2	O
TAM	O
differentiation	O
,	O
as	O
shown	O
by	O
others	O
[	O
6	O
,	O
55	O
],	O
but	O
as	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
(	O
MCF	O
-	O
7	O
and	O
T47D	O
)	O
that	O
do	O
not	O
produce	O
M	B-GP
-	I-GP
CSF	I-GP
also	O
affected	O
the	O
M2	O
phenotype	O
,	O
inducing	O
M2a	O
differentiation	O
,	O
we	O
think	O
there	O
are	O
other	O
relevant	O
M2	O
skewing	O
factors	O
,	O
which	O
our	O
work	O
cannot	O
address	O
.	O

The	O
discovery	O
of	O
such	O
factors	O
is	O
of	O
utmost	O
relevance	O
,	O
and	O
calls	O
for	O
further	O
studies	O
.	O

Conclusions	O

This	O
study	O
combines	O
several	O
lines	O
of	O
evidence	O
for	O
the	O
importance	O
of	O
TAM	O
polarization	O
status	O
in	O
breast	B-DS
cancer	I-DS
progression	O
.	O

For	O
the	O
first	O
time	O
,	O
it	O
is	O
clear	O
that	O
CD163	B-GP
+	O
TAMs	O
associate	O
with	O
other	O
known	O
prognostic	O
factors	O
like	O
fast	O
proliferation	O
,	O
poor	O
differentiation	O
and	O
ER	B-GP
-	O
negativity	O
.	O

CD163	B-GP
+	O
TAMs	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
RFS	O
according	O
to	O
the	O
multivariate	O
Cox	O
model	O
.	O

The	O
presented	O
ex	O
vivo	O
results	O
are	O
to	O
our	O
knowledge	O
the	O
first	O
demonstrating	O
the	O
modulation	O
of	O
macrophage	O
differentiation	O
solely	O
by	O
breast	B-DS
cancer	I-DS
cell	O
-	O
secreted	O
factors	O
,	O
providing	O
evidence	O
for	O
the	O
mechanisms	O
of	O
breast	B-DS
cancer	I-DS
macrophage	O
education	O
behind	O
clinical	O
findings	O
.	O

Particularly	O
,	O
the	O
mesenchymal	O
-	O
type	O
cell	O
line	O
MDA	O
-	O
MB231	O
polarizes	O
macrophages	O
toward	O
a	O
mixed	O
M2a	O
/	O
M2c	O
status	O
.	O

It	O
is	O
therefore	O
rational	O
to	O
venture	O
that	O
the	O
screening	O
of	O
TAM	O
activation	O
in	O
breast	B-DS
cancer	I-DS
patients	O
could	O
be	O
useful	O
in	O
predicting	O
patients	O
with	O
a	O
high	O
metastatic	O
risk	O
.	O

The	O
knowledge	O
of	O
TAM	O
activation	O
status	O
may	O
allow	O
the	O
therapeutic	O
targeting	O
of	O
TAMs	O
,	O
once	O
TAMs	O
targeting	O
/	O
modulating	O
agents	O
pass	O
clinical	O
trials	O
and	O
become	O
widely	O
available	O
.	O

These	O
include	O
bisphosphonates	O
[	O
56	O
];	O
M	B-GP
-	I-GP
CSF	I-GP
and	O
M	B-GP
-	I-GP
CSFR	I-GP
inhibitors	O
and	O
targeting	O
antibodies	B-GP
[	O
57	O
],	O
NCT01316822	O
,	O
NCT01444404	O
;	O
anti	O
-	O
macrophage	B-GP
migration	I-GP
inhibitory	I-GP
factor	I-GP
,	O
NCT01765790	O
and	O
L	O
-	O
MTP	O
-	O
PE	O
,	O
NCT00631631	O
.	O

There	O
is	O
a	O
scarcity	O
of	O
therapeutic	O
options	O
for	O
patients	O
with	O
triple	O
-	O
negative	O
metastatic	B-DS
breast	I-DS
cancer	I-DS
,	O
and	O
growing	O
resistance	O
to	O
the	O
available	O
options	O
biased	O
by	O
a	O
continuous	O
focus	O
on	O
cancer	B-DS
cell	O
targets	O
,	O
which	O
are	O
by	O
nature	O
genetically	O
unstable	O
and	O
prone	O
to	O
mutations	O
.	O

Approaches	O
such	O
as	O
ours	O
fuel	O
a	O
necessary	O
paradigm	O
change	O
,	O
contributing	O
to	O
the	O
notion	O
that	O
the	O
immunological	O
tumor	B-DS
microenvironment	O
should	O
be	O
taken	O
into	O
account	O
in	O
the	O
development	O
of	O
new	O
multi	O
-	O
target	O
cancer	B-DS
therapies	O
.	O

Immunohistochemical	O
analysis	O
conditions	O
.	O
(	O
PDF	O
273	O
kb	O
)	O

Tissue	O
microarray	O
(	O
TMA	O
)	O
analysis	O
of	O
recurrence	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
curves	O
related	O
to	O
the	O
macrophage	O
markers	O
A	O
CD68	B-GP
B	O
CD163	B-GP
and	O
C	O
HLA	B-GP
-	I-GP
DRIIα	I-GP
.	O
(	O
PDF	O
22622	O
kb	O
)	O

Flow	O
cytometry	O
analysis	O
of	O
CD14	B-GP
+	O
cells	O
differentiated	O
for	O
5	O
days	O
with	O
or	O
without	O
50	O
%	O
conditioned	O
media	O
(	O
CM	O
),	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
A	O
mean	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
CD14	B-GP
B	O
CD16	B-GP
C	O
CD64	B-GP
D	O
CD163	B-GP
E	O
CD86	B-GP
and	O
F	O
CD200R	B-GP
,	O
normalized	O
to	O
MFI	O
of	O
unstained	O
cells	O
;	O
n	O
=	O
3	O
,	O
***	O
p	O
<	O
0	O
.	O
0005	O
.	O
(	O
PDF	O
1833	O
kb	O
)	O

Flow	O
cytometry	O
analysis	O
of	O
CD14	B-GP
+	O
cells	O
differentiated	O
for	O
5	O
days	O
in	O
the	O
presence	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
with	O
or	O
without	O
50	O
%	O
conditioned	O
media	O
(	O
CM	O
)	O
A	O
mean	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
CD14	B-GP
B	O
CDC16	B-GP
and	O
C	O
CD64	B-GP
normalized	O
to	O
MFI	O
of	O
unstained	O
cells	O
;	O
n	O
=	O
3	O
.	O
(	O
PDF	O
2112	O
kb	O
)	O

Representative	O
flow	O
cytometry	O
dot	O
plot	O
of	O
IL	B-GP
-	I-GP
10	I-GP
macrophages	O
A	O
human	B-OG
macrophages	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
10	I-GP
with	O
or	O
without	O
breast	B-DS
cancer	I-DS
cell	O
line	O
conditioned	O
media	O
(	O
CM	O
),	O
detected	O
with	O
antibodies	B-GP
against	O
CD14	B-GP
,	O
CD16	B-GP
and	O
CD163	B-GP
B	O
mean	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
the	O
analyzed	O
surface	O
-	O
markers	O
.	O
(	O
PDF	O
18647	O
kb	O
)	O

Representative	O
flow	O
cytometry	O
dot	O
plot	O
of	O
IL	B-GP
-	I-GP
4	I-GP
macrophages	O
A	O
human	B-OG
macrophages	O
in	O
the	O
presence	O
of	O
IL	B-GP
-	I-GP
4	I-GP
with	O
or	O
without	O
breast	B-DS
cancer	I-DS
cell	O
line	O
conditioned	O
media	O
(	O
CM	O
),	O
detected	O
with	O
antibodies	B-GP
against	O
CD14	B-GP
,	O
CD16	B-GP
,	O
CD163	B-GP
,	O
CD200R	B-GP
and	O
CD86	B-GP
B	O
mean	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
the	O
analyzed	O
surface	O
-	O
markers	O
.	O
(	O
PDF	O
2715	O
kb	O
)	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

